New evidence for Ozempic brain protection has emerged from one of the largest studies of its kind, linking the blockbuster diabetes drug semaglutide to a sharply lower risk of Alzheimer’s disease. Researchers at Case Western Reserve School of Medicine analysed three years of electronic health records for nearly one million Americans with type 2 diabetes and found that those prescribed semaglutide had a 40 to 70 per cent lower risk of a first-time Alzheimer’s diagnosis than patients taking seven other diabetes medicines.
Semaglutide, sold under the brand names Ozempic, Wegovy and Rybelsus by Danish drugmaker Novo Nordisk, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes and obesity. The study, published in the journal Alzheimer’s and Dementia, compared it with metformin, DPP-4 inhibitors and five other classes of glucose-lowering medicines. It is the largest analysis yet to examine Ozempic brain protection in routine clinical records.
The research adds to a growing body of work suggesting the medicine may do more than control blood sugar. A separate cohort study of 60,860 patients, published in JAMA Network Open in 2025, found that users of semaglutide or tirzepatide had significantly lower risks of dementia, stroke and death from any cause than users of other antidiabetic drugs. Benefits were largest in adults over 60, women and people with a body mass index between 30 and 40, adding weight to the case for Ozempic brain protection.
Ozempic brain protection: what the studies found
Lead researcher Rong Xu, a professor of biomedical informatics at Case Western Reserve University, said the results matched the team’s expectations given earlier work showing semaglutide can reduce inflammation, prevent neuron damage, promote weight loss and protect against cardiovascular disease. By targeting these risk factors, the researchers argue, semaglutide may help prevent or slow the development of Alzheimer’s symptoms.
A separate study funded by the National Institutes of Health and led by the University of Florida reached a similar conclusion. Analysing records from more than 300,000 adults with type 2 diabetes, it found that use of GLP-1 receptor agonists and SGLT2 inhibitors was associated with a significant reduction in the risk of Alzheimer’s disease and related dementias compared with older medicines such as sulfonylureas or DPP-4 inhibitors.
- 40 to 70 per cent lower risk of first-time Alzheimer’s diagnosis — the strongest Ozempic brain protection signal yet
- Significantly lower dementia, stroke and mortality risk in a 60,860-patient cohort
- Benefits largest in adults over 60, women and people with obesity
How Ozempic brain protection might work
Scientists say several mechanisms could explain this apparent Ozempic brain protection. Type 2 diabetes and obesity damage blood vessels, promote chronic inflammation and impair insulin signalling in the brain — all processes implicated in dementia. By controlling blood sugar, reducing weight and calming inflammation, semaglutide may shield neurons from the damage that leads to cognitive decline. A review of laboratory and animal studies has also suggested GLP-1 drugs may help lower the brain proteins associated with Alzheimer’s disease.
Researchers caution, however, that the findings come from observational studies, which can show associations but cannot prove the drug itself prevents dementia. The Case Western team also stressed that its study was not designed to examine whether semaglutide lowers Alzheimer’s risk in people without diabetes.
Ozempic brain protection needs further trials
Not every trial has been encouraging. Two large randomised trials of semaglutide in people with early-stage Alzheimer’s found it did not slow cognitive decline compared with a placebo, although some biological markers of the disease improved. The results suggest the drug may be more useful for prevention in at-risk patients than for treating established disease. They do not overturn the broader Ozempic brain protection hypothesis, which concerns prevention rather than treatment.
Even so, researchers say the observational signals are now large enough to justify further clinical evaluation of Ozempic brain protection. Drugmakers including Novo Nordisk and Eli Lilly are continuing to study GLP-1 medicines for cognitive endpoints, and neurologists are debating whether to discuss the potential benefits with patients worried about memory.
For now, doctors emphasise that controlling diabetes, maintaining a healthy weight and staying physically active remain the best-established ways to protect the brain. Whether semaglutide earns a formal role in dementia prevention will depend on the randomised trials still to come.